Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres
Authors:
- 3 October 2018
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 42 (1) , 35-43
Abstract
Surveillance of drug safety during pregnancy is a special interest of pharmacovigilance (PV). The role that national PV centres take in this field is, however, unclear.Keywords
This publication has 13 references indexed in Scilit:
- Medication Safety During Pregnancy: Improving Evidence‐Based PracticeJournal of Midwifery & Women's Health, 2016
- Experiences and Lessons From Implementing Cohort Event Monitoring Programmes for Antimalarials in Four African Countries: Results of a Questionnaire-Based SurveyDrug Safety, 2015
- Update on the Teratogenicity of Maternal Mycophenolate MofetilJournal of Pediatric Genetics, 2015
- A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment CommitteeDrug Safety, 2014
- Healthcare databases in Europe for studying medicine use and safety during pregnancyPharmacoepidemiology and Drug Safety, 2014
- WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting SystemsDrug Safety, 2013
- Post‐market drug safety evidence sources: an analysis of FDA drug safety communicationsPharmacoepidemiology and Drug Safety, 2012
- Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelinesBirth Defects Research Part A: Clinical and Molecular Teratology, 2008
- Systematic Identification of Drugs That Cause Birth Defects — A New OpportunityNew England Journal of Medicine, 2003
- Teratogen update: Carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in uteroTeratology, 1995